Characteristics | Remission patients | Non-progression patients | Progression patients | P-value |
---|---|---|---|---|
 | (n = 369) | (n = 308) | (n = 61) |  |
ALB g/L at month 3 | 40.9 ± 4.9 | 41.3 ± 0.6 | 39.0 ± 1.7 | NS |
ALB g/L at month 6 | 42.9 ± 4.2 | 43.5 ± 0.6 | 40.5 ± 1.3 | 0.02 |
TA-ALB g/L | 42.1 ± 3.8 | 42.7 ± 0.5 | 39.4 ± 1.2 | 0.01 |
SCr μmol/L at month 3 | 90.2 ± 35.5 | 82.7 ± 3.9 | 121.6 ± 13.9 | 0.01 |
SCr μmol/L at month 6 | 88.2 ± 37.5 | 80.3 ± 4.2 | 121.3 ± 14.1 | 0.002 |
TA-SCr μmol/L | 91.8 ± 46.8 | 80.5 ± 4.2 | 136.7 ± 21.0 | 0.002 |
BUN mmol/L at month 3 | 7.4 ± 2.9 | 6.8 ± 0.3 | 9.8 ± 1.1 | 0.01 |
BUN mmol/L at month 6 | 6.5 ± 2.3 | 6.1 ± 0.3 | 8.0 ± 0.9 | 0.02 |
TA-BUN mmol/L | 6.6 ± 2.2 | 6.1 ± 0.2 | 8.6 ± 0.9 | 0.004 |
eGFR (ml/min/1.73 m2) at month 3 | 85.5 ± 33.1 | 90.8 ± 4.4 | 63.4 ± 8.2 | 0.01 |
eGFR (ml/min/1.73 m2) at month 6 | 88.9 ± 33.7 | 95.1 ± 4.6 | 63.1 ± 7.8 | 0.003 |
TA-eGFR (ml/min/1.73 m2) | 88.5 ± 33.2 | 95.1 ± 4.5 | 61.9 ± 8.1 | 0.002 |
UPE (g/d) at month 3 | 0.7 (0.4-1.3) | 0.6 (0.2-1.0) | 1.3 (0.7-2.0) | 0.04 |
UPE (g/d) at month 6 | 0.4 (0.2-0.7) | 0.4 (0.1-0.7) | 0.4 (0.2-1.2) | NS |
TA-UPE (g/d) | 1.1 (0.6-1.6) | 1.0 (0.6-1.4) | 1.3 (1.0-2.1) | NS |